NCT02196181

Disease Type: Melanoma
Status: Open

Trial Information

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact: